Bank Of America Corp Exelixis, Inc. Call Options Transaction History

Bank Of America Corp

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $1.65 Million - $1.92 Million	81,100 New	81,100 $1.82 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $3.63 Million - $4.56 Million	-188,800 Reduced 39.59%	288,100 $6.91 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $7 Million - $7.9 Million	385,500 Added 421.77%	476,900 $9.11 Million
Q1 2023 May 12, 2023	BUY	$16.3 - $19.41 $1.49 Million - $1.77 Million	91,400 New	91,400 $1.77 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $326,000 - $422,800	20,000 New	20,000 $423,000

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.63B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.